share_log

Illumina | 10-Q: Q2 2024 Earnings Report

Illumina | 10-Q: Q2 2024 Earnings Report

Illumina | 10-Q:2024财年二季报
美股SEC公告 ·  2024/08/08 05:32

Moomoo AI 已提取核心信息

Illumina, a global leader in DNA sequencing and array-based technologies, has reported a decrease in revenue for the year-to-date (YTD) 2024. The company's revenue fell by 3% to $2,188 million compared to $2,263 million in YTD 2023, primarily due to a decline in sequencing instruments revenue. Despite this, Illumina's gross margin improved to 63.5% in YTD 2024 from 61.3% in YTD 2023, attributed to a favorable mix of sequencing consumables and operational cost savings. However, the company experienced a significant loss from operations, which increased to $1,749 million in YTD 2024 from $152 million in YTD 2023, largely due to goodwill and intangible impairment charges. The effective tax rate for YTD 2024 was (1.4)%, a change from (38.5)% in YTD 2023. Illumina ended Q2 2024 with $994 million in cash, cash equivalents, and short-term...Show More
Illumina, a global leader in DNA sequencing and array-based technologies, has reported a decrease in revenue for the year-to-date (YTD) 2024. The company's revenue fell by 3% to $2,188 million compared to $2,263 million in YTD 2023, primarily due to a decline in sequencing instruments revenue. Despite this, Illumina's gross margin improved to 63.5% in YTD 2024 from 61.3% in YTD 2023, attributed to a favorable mix of sequencing consumables and operational cost savings. However, the company experienced a significant loss from operations, which increased to $1,749 million in YTD 2024 from $152 million in YTD 2023, largely due to goodwill and intangible impairment charges. The effective tax rate for YTD 2024 was (1.4)%, a change from (38.5)% in YTD 2023. Illumina ended Q2 2024 with $994 million in cash, cash equivalents, and short-term investments. The company's financial performance has been influenced by macroeconomic factors, competitive challenges, and geopolitical tensions. Illumina completed the Spin-Off of GRAIL, retaining approximately 14.5% of GRAIL's shares. The company operates in two segments: Core Illumina and GRAIL, with Core Illumina representing its primary business operations. Illumina's future plans include cost reduction initiatives to improve margins and investments in high-growth areas, despite expecting continued impact from external economic and market factors.
全球DNA测序和基于阵列技术的领导者Illumina报告了2024年迄今为止的营业收入下降情况。该公司的营业收入从2023年迄今为止的226300万美元下降了3%,降至218800万美元,主要是由于测序仪器收入下降。尽管如此,Illumina的毛利率从2023年迄今为止的61.3%提高到了2024年迄今为止的63.5%,归功于测序耗材和运营成本节约的有利组合。然而,该公司经营亏损显著增加,2024年迄今为止从2023年迄今为止的15200万美元增加到174900万美元,主要是由于商誉和无形资产减值费用。2024年迄今为止的有效税率为(1.4)%,与2023年迄今为止的(38.5)%不同。 Il...展开全部
全球DNA测序和基于阵列技术的领导者Illumina报告了2024年迄今为止的营业收入下降情况。该公司的营业收入从2023年迄今为止的226300万美元下降了3%,降至218800万美元,主要是由于测序仪器收入下降。尽管如此,Illumina的毛利率从2023年迄今为止的61.3%提高到了2024年迄今为止的63.5%,归功于测序耗材和运营成本节约的有利组合。然而,该公司经营亏损显著增加,2024年迄今为止从2023年迄今为止的15200万美元增加到174900万美元,主要是由于商誉和无形资产减值费用。2024年迄今为止的有效税率为(1.4)%,与2023年迄今为止的(38.5)%不同。 Illumina在二季度以99400万美元现金、现金等价物和短期投资结束。该公司的财务表现受到宏观经济因素、竞争挑战和地缘政治紧张局势的影响。Illumina完成了GRAIL的分拆,保留了GRAIL股份约14.5%。该公司分为两个业务领域:Core Illumina和GRAIL,其中Core Illumina代表其主要业务运营。Illumina的未来计划包括成本削减计划以提高利润率以及投资于高增长领域,尽管预计将持续受到来自外部经济和市场因素的影响。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息